What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Disease
- Surgery
Janet E. Pope spends much of her time researching Internal medicine, Surgery, Randomized controlled trial, Placebo and Physical therapy.
Her research on Internal medicine frequently links to adjacent areas such as Immunology.
Her biological study spans a wide range of topics, including Gastroenterology, Adverse effect and Severity of illness.
Her Randomized controlled trial research includes themes of Meta-analysis, Clinical trial and Visual analogue scale.
The study incorporates disciplines such as Osteoarthritis and Strictly standardized mean difference, Confidence interval in addition to Placebo.
Her Physical therapy research incorporates elements of Psychological intervention, Rheumatism, MEDLINE and Psychosocial.
Her most cited work include:
- 2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative (1669 citations)
- A Randomized Trial of Arthroscopic Surgery for Osteoarthritis of the Knee (1516 citations)
- Mortality in systemic lupus erythematosus. (771 citations)
What are the main themes of her work throughout her whole career to date?
Janet E. Pope focuses on Internal medicine, Rheumatoid arthritis, Cohort, Rheumatology and Physical therapy.
Her work deals with themes such as Placebo and Surgery, which intersect with Internal medicine.
Janet E. Pope has researched Rheumatoid arthritis in several fields, including Methotrexate and Arthritis.
Her Cohort study also includes
- Early arthritis that intertwine with fields like Early ra,
- Severity of illness most often made with reference to Cohort study,
- Disease, which have a strong connection to Intensive care medicine.
Her Rheumatology research is multidisciplinary, incorporating elements of Rheumatism and Family medicine.
Her Physical therapy research includes elements of Clinical trial and Quality of life.
She most often published in these fields:
- Internal medicine (63.29%)
- Rheumatoid arthritis (26.88%)
- Cohort (23.50%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (63.29%)
- Rheumatoid arthritis (26.88%)
- Cohort (23.50%)
In recent papers she was focusing on the following fields of study:
Her primary scientific interests are in Internal medicine, Rheumatoid arthritis, Cohort, Rheumatology and In patient.
Her research on Internal medicine often connects related topics like Placebo.
Her Rheumatoid arthritis research incorporates themes from Adverse effect, Methotrexate and Proportional hazards model.
The Cohort study combines topics in areas such as Logistic regression, Early arthritis, Early Inflammatory Arthritis, Cohort study and Prospective cohort study.
The concepts of her Randomized controlled trial study are interwoven with issues in Tocilizumab, Quality of life and Number needed to treat.
Her Scleroderma study incorporates themes from Fibrosis, Autoantibody and Clinical trial.
Between 2017 and 2021, her most popular works were:
- Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) (130 citations)
- Treatment Algorithms for Systemic Sclerosis According to Experts. (85 citations)
- Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial (66 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
Her primary areas of study are Internal medicine, Rheumatoid arthritis, Placebo, Cohort and Randomized controlled trial.
Janet E. Pope undertakes multidisciplinary investigations into Internal medicine and In patient in her work.
Her studies deal with areas such as Gastroenterology, Physical therapy, Methotrexate and Combination therapy as well as Rheumatoid arthritis.
Her studies in Placebo integrate themes in fields like Clinical endpoint, Clinical trial and Vital capacity.
Her study in Cohort is interdisciplinary in nature, drawing from both Logistic regression, Obesity, Cohort study, Proportional hazards model and Prospective cohort study.
Her Randomized controlled trial study combines topics in areas such as Psychological intervention, Tocilizumab, Meta-analysis and MEDLINE.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
